Sandoz - A healthy decision in Generic Pharmaceuticals

Sandoz Romania creates value by developing, manufacturing and selling a broad portfolio, covering all therapy areas, of affordable off-patent and patent-free pharmaceuticals, Essentially, Sandoz' aim is to improve people's lives all over the world

Sandoz' aspirations are to retain and expand the leading position of high quality generics, to earn clients' trust through extensive experience and innovation capabilities, to be recognized as top consumer-friendly pharmaceutical company, and to act as an exemplary corporate citizen.

Company's portfolio has extended on other therapy areas(cardiology and neurology), intending to launch new products in the fields with the most important growth, meeting this way the treatment needs of the patients.

Sandoz Romania have a competitive and broad product portfolio offering around 100 active ingredients with more than 200 dosage forms. The combined company employs more than 255 peoples and its headquarters is located in Targu-Mures.

Sandoz, a Novartis company, is a world leader in generic pharmaceuticals. The company develops, manufactures and markets these medicines as well as pharmaceutical and biotechnological active ingredients.

In 2005, Sandoz acquired Hexal, one of Germany's leading generics company, and Eon Labs, one of the fastest-growing generic pharmaceuticals companies in the US. These acquisitions significantly strengthen the Sandoz technology base, particularly in the application of "difficult-to-make" generics: transdermal patches, inhalation products, sustained-release implants and multi-particulate drug-delivery dosage forms. Also expanded are the traditionally strong capabilities in pharmaceuticals, biopharmaceuticals and anti-infectives.

The company is competitive with its leading presence in key markets, including the US and Germany, and a comprehensive product portfolio of more than 600 active ingredi-ents in more than 5,000 dosage forms. Combining the strengths of the companies, including the Sandoz global network, Hexal's registration and development activities and Eon Labs's performance in ANDA filings, the company aims to achieve significant product approvals annually from the global organization.

Sandoz reported generic pharmaceutical sales in 2005 were USD 4.7 billion. By now, the combined company employs more than 20,000 people in 110 countries. Its global headquarters are based in Holzkirchen, Germany, located just south of Munich.

Generic pharmaceuticals are the bioequivalent of an innovative, brand name product. This includes dosage form, safety, strength, route of administration, quality, performance characteristics and intended use. Generics are held to the same strict standards as the innovator product, dictated by the U.S. Food and Drug Administration (FDA) and other regulatory agencies throughout the world. Although generic pharmaceuticals are chemically identical to their branded counterparts, they traditionally cost consumers less than the brand product.

The finished dosage forms are sold to wholesalers, pharmacies, hospitals and other healthcare outlets. Our Anti-Infectives unit manufactures active pharmaceutical ingredients and their intermediates for internal requirements and industrial partners.

Download Novartis annual report